ResMed (RMD) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $226.85 +0.38%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $0.65, in-line with the analyst estimate of $0.65. Revenue for the quarter came in at $422.5 million versus the consensus estimate of $425.76 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Radnostix revenue falls 27% amid product recalls and FDA actions
- Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
